194471-87-9 Usage
General Description
FMOC-3-AMINO-3-(4-CHLOROPHENYL)PROPIONIC ACID is a chemical compound with the molecular formula C21H17ClNO4. It is a derivative of amino acid, 3-amino-3-(4-chlorophenyl)propionic acid, with a fluorenylmethoxycarbonyl (FMOC) protecting group attached. FMOC-3-AMINO-3-(4-CHLOROPHENYL)PROPIONIC ACID is commonly used in peptide synthesis as a protecting group for the amino group of the amino acid, allowing for selective deprotection and subsequent coupling reactions in the synthesis of peptides. It is also utilized in the study of peptide chemistry and in the development of pharmaceutical drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 194471-87-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,4,4,7 and 1 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 194471-87:
(8*1)+(7*9)+(6*4)+(5*4)+(4*7)+(3*1)+(2*8)+(1*7)=169
169 % 10 = 9
So 194471-87-9 is a valid CAS Registry Number.
InChI:InChI=1/C24H20ClNO4/c25-16-11-9-15(10-12-16)22(13-23(27)28)26-24(29)30-14-21-19-7-3-1-5-17(19)18-6-2-4-8-20(18)21/h1-12,21-22H,13-14H2,(H,26,29)(H,27,28)
194471-87-9Relevant articles and documents
Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists
Sulyok,Gibson,Goodman,H?lzemann,Wiesner,Kessler
, p. 1938 - 1950 (2007/10/03)
The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.